



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



July 22, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Intimation of Board Meeting under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (“the Company”) is scheduled to be held on Wednesday, July 29, 2026 to consider and approve, inter-alia the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Further, in continuation of our letter dated June 26, 2026, regarding Intimation of closure of Trading Window, we would like to inform that the trading window for trading in Securities of the company shall remain closed till July 31, 2026.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal
Company Secretary & Compliance Office